The book Tissue Engineering of Vascular Prosthetic Grafts, edited by Peter Zilla and Howard Greisler, explores the basic biology, clinical background and pathology of synthetic vascular graft ...

A breakthrough in life-saving medical technology has arrived. The U.S. Food and Drug Administration (FDA) has officially ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

Silver Spring, Md Thursday, December 26, 2024, 11:00 Hrs [IST] ...

A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...

There is a considerable clinical need for alternatives to the autologous vein and artery tissues used for vascular reconstructive surgeries such as CABG, lower limb bypass, arteriovenous shunts ...

The first acellular tissue engineered vessel for adults with vascular trauma in a bodily extremity has been approved by the U.S. FDA. Symvess, which comes from regenerative tissue developer Humacyte ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Humacyte Inc. shares surged over 70% early on Friday, reaching their highest levels in over a month amid skyrocketing retail ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod ...

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.